AU2011250485B2 - Pharmaceutical composition and method for treating hypertension - Google Patents

Pharmaceutical composition and method for treating hypertension Download PDF

Info

Publication number
AU2011250485B2
AU2011250485B2 AU2011250485A AU2011250485A AU2011250485B2 AU 2011250485 B2 AU2011250485 B2 AU 2011250485B2 AU 2011250485 A AU2011250485 A AU 2011250485A AU 2011250485 A AU2011250485 A AU 2011250485A AU 2011250485 B2 AU2011250485 B2 AU 2011250485B2
Authority
AU
Australia
Prior art keywords
dextromethorphan
amlodipine
hypertension
pharmaceutical composition
blood pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011250485A
Other languages
English (en)
Other versions
AU2011250485A1 (en
Inventor
Jaw-Wen Chen
Shin-Yi Juang
Hsi-Chieh Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TSH BIOPHARM CORP Ltd
Original Assignee
TSH BIOPHARM CORP Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TSH BIOPHARM CORP Ltd filed Critical TSH BIOPHARM CORP Ltd
Publication of AU2011250485A1 publication Critical patent/AU2011250485A1/en
Application granted granted Critical
Publication of AU2011250485B2 publication Critical patent/AU2011250485B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011250485A 2010-05-03 2011-04-29 Pharmaceutical composition and method for treating hypertension Ceased AU2011250485B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33054010P 2010-05-03 2010-05-03
US61/330,540 2010-05-03
PCT/CN2011/073560 WO2011137734A1 (en) 2010-05-03 2011-04-29 Pharmaceutical composition and method for treating hypertension

Publications (2)

Publication Number Publication Date
AU2011250485A1 AU2011250485A1 (en) 2012-12-06
AU2011250485B2 true AU2011250485B2 (en) 2016-07-07

Family

ID=44903590

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011250485A Ceased AU2011250485B2 (en) 2010-05-03 2011-04-29 Pharmaceutical composition and method for treating hypertension

Country Status (11)

Country Link
US (2) US20130053411A1 (enExample)
EP (1) EP2566478A4 (enExample)
JP (1) JP5847162B2 (enExample)
KR (1) KR20130061148A (enExample)
CN (1) CN102869360B (enExample)
AU (1) AU2011250485B2 (enExample)
BR (1) BR112012028153A2 (enExample)
MY (1) MY161853A (enExample)
RU (1) RU2571284C2 (enExample)
TW (1) TWI583383B (enExample)
WO (1) WO2011137734A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014126972A1 (en) * 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN107921042A (zh) * 2015-08-20 2018-04-17 东生华制药股份有限公司 包含氨氯地平和右美沙芬的药物组合物
EP4620525A3 (en) 2016-12-14 2025-12-03 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
DK4101454T3 (da) 2017-01-25 2024-06-17 The George Inst For Global Health Sammensætninger til behandling af hypertension
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003137A1 (en) * 1990-08-23 1992-03-05 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
WO2003097608A2 (en) * 2002-05-17 2003-11-27 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20050107415A1 (en) * 2002-05-17 2005-05-19 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20080039484A1 (en) * 2006-08-10 2008-02-14 Hua-Lin Wu Methods and Compositions for Preventing or Treating Cardiovascular Disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676177A (en) 1949-11-09 1954-04-20 Hoffmann La Roche Process for the preparation of optically active 3-methoxy-n-methyl morphinans and salts thereof
GB8710493D0 (en) 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
JPH04368338A (ja) * 1991-06-12 1992-12-21 Taisho Pharmaceut Co Ltd 鎮咳剤
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US5560913A (en) 1995-01-27 1996-10-01 The Procter & Gamble Company Pharmaceutical compositions
KR20040097375A (ko) 2002-04-23 2004-11-17 시오노기 앤드 컴파니, 리미티드 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
KR100476636B1 (ko) 2002-09-11 2005-03-17 한림제약(주) 엘-(+)-타르트레이트를 이용한 에스-(-)-암로디핀의 제조방법
CL2003002653A1 (es) * 2002-12-18 2005-04-22 Wyeth Corp Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar
WO2006033965A2 (en) 2004-09-16 2006-03-30 The Trustees Of The University Of Pennsylvania Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
US20060188450A1 (en) * 2005-02-24 2006-08-24 Tim Clarot System and method for suppressing a cough
US7939567B2 (en) * 2006-02-24 2011-05-10 Blue Blood Biotech Corp. Dextromethorphan-based method for treating acne
BRPI0819883A2 (pt) * 2007-11-28 2017-05-23 Sequoia Pharmaceuticals Inc composições e métodos para inibir citocromo p450 2d6

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003137A1 (en) * 1990-08-23 1992-03-05 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
WO2003097608A2 (en) * 2002-05-17 2003-11-27 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20050107415A1 (en) * 2002-05-17 2005-05-19 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20080039484A1 (en) * 2006-08-10 2008-02-14 Hua-Lin Wu Methods and Compositions for Preventing or Treating Cardiovascular Disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dickson et al, American Journal of Cardiovascular Drugs (2008), Vol. 8, No. 1, Pages 45-50 *
Gojanovic et al, Journal of the Renin-Angiotensin-Aldosterone System (2008), Vol. 9, No. 1, Pages 1-9 *

Also Published As

Publication number Publication date
TWI583383B (zh) 2017-05-21
KR20130061148A (ko) 2013-06-10
RU2012151051A (ru) 2014-06-10
EP2566478A1 (en) 2013-03-13
TW201206437A (en) 2012-02-16
EP2566478A4 (en) 2014-04-30
MY161853A (en) 2017-05-15
AU2011250485A1 (en) 2012-12-06
BR112012028153A2 (pt) 2018-08-07
CN102869360A (zh) 2013-01-09
JP5847162B2 (ja) 2016-01-20
WO2011137734A1 (en) 2011-11-10
RU2571284C2 (ru) 2015-12-20
JP2013525460A (ja) 2013-06-20
US9744165B2 (en) 2017-08-29
US20160235741A1 (en) 2016-08-18
US20130053411A1 (en) 2013-02-28
CN102869360B (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
US9744165B2 (en) Method for treating hypertension
KR100442675B1 (ko) 데스카르보에톡시로라타딘을이용한알레르기성비염과다른질병의치료방법과조성물
Bang et al. Lercanidipine: a review of its efficacy in the management of hypertension
AU2009201408A1 (en) Combination of a DPP IV inhibitor and an antiobesity or appetite regulating agent
EP2968227B1 (en) S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
JP2008519835A (ja) 大動脈内皮細胞の一酸化窒素放出に対するアムロジピン及びアトルバスタチンの相乗効果
EP1715863B1 (en) Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
SG190326A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
Guarneri et al. In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers
JPS63310867A (ja) 抗鬱病剤作用を有する新規な結合生成物
US9687457B2 (en) Detrusor hyperactivity with impaired contractility ameliorating agent
JP5441052B2 (ja) アルツハイマー病治療薬
WO2014034871A1 (ja) 脂質異常症の予防又は治療薬
EP0965341A2 (en) Combination of dofetilide and a calcium channel blocker
WO2012041258A1 (en) Compositions and methods for treating hypertension using eprosartan and amlodipine
CN109476583B (zh) 作为神经递质释放剂的插烯苯乙胺
KR20110073575A (ko) 당뇨병성 신증의 치료제
Clapham No. 2, zyxwvutsrqponmlkjihg
MXPA99004460A (en) Combination of dofetilida and a blocking of the calculates
HK1008185B (en) Use of descarboethoxyloratadine or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating allergic rhinitis
HK1220609B (en) S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired